Andreas Krause

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4639448/publications.pdf

Version: 2024-02-01

56	2,135	331670	233421
papers	citations	21	45
		h-index	g-index

58	58	58	3185
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A standard curve based method for relative real time PCR data processing. BMC Bioinformatics, 2005, 6, 62.	2.6	780
2	Estrogen-Independent Proliferation Is Present in Estrogen-ReceptorHER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole. Journal of Clinical Oncology, 2006, 24, 3019-3025.	1.6	170
3	Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation, 2003, 75, 1323-1330.	1.0	96
4	Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenetics and Genomics, 2007, 17, 813-826.	1.5	94
5	Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole. Journal of Clinical Oncology, 2009, 27, 1382-1387.	1.6	93
6	Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics, 2010, 2, 364-388.	4.5	75
7	The validation of new aromatase monoclonal antibodies for immunohistochemistryâ€"A correlation with biochemical activities in 46 cases of breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 35-39.	2.5	62
8	Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P₁receptor modulator: Favorable impact of dose up-titration. Journal of Clinical Pharmacology, 2014, 54, 179-188.	2.0	60
9	Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood, 2004, 103, 2929-2935.	1.4	57
10	Biomarkerâ€guided clinical development of the firstâ€inâ€class antiâ€inflammatory FPR2/ALX agonist ACTâ€389949. British Journal of Clinical Pharmacology, 2017, 83, 476-486.	2.4	48
11	Efficacy of Rivastigmine in Alzheimerâ€™s Disease Patients with Rapid Disease Progression: Results of a Meta-Analysis. Dementia and Geriatric Cognitive Disorders, 2005, 20, 192-197.	1.5	46
12	Optimized Protocol for Linear RNA Amplification and Application to Gene Expression Profiling of Human Renal Biopsies. BioTechniques, 2003, 34, 546-556.	1.8	43
13	Modeling of Discontinuous Relationships in Biology with Censored Regression. American Naturalist, 1994, 143, 494-507.	2.1	36
14	Visualization and Communication of Pharmacometric Models With Berkeley Madonna. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-20.	2.5	33
15	An integrated view of aromatase and its inhibition. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 413-421.	2.5	32
16	A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial. Clinical Drug Investigation, 2014, 34, 807-818.	2.2	31
17	Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelionâ€451840 in an induced blood stage malaria study in healthy subjects. British Journal of Clinical Pharmacology, 2016, 82, 412-421.	2.4	28
18	Confidence and Prediction Intervals for Pharmacometric Models. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 360-373.	2.5	26

#	Article	IF	Citations
19	Predicting response and resistance to endocrine therapy. Cancer, 2008, 112, 689-694.	4.1	25
20	Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. British Journal of Clinical Pharmacology, 2016, 82, 369-379.	2.4	25
21	Aromatase inhibitorsâ€"Gene discovery. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 130-142.	2.5	24
22	Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 261-278.	1.8	22
23	Aromatase inhibitors: Cellular and molecular effects. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 83-89.	2.5	21
24	Mitigation of Initial Cardiodynamic Effects of the S1P₁ Receptor Modulator Ponesimod Using a Novel Upâ€Ťitration Regimen. Journal of Clinical Pharmacology, 2017, 57, 401-410.	2.0	16
25	Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P₁ Receptor Modulator Ponesimod. Clinical Pharmacology and Therapeutics, 2018, 103, 1083-1092.	4.7	15
26	Modeling the Effect of the Selective S1P1 Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes. Pharmaceutical Research, 2017, 34, 599-609.	3.5	11
27	Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis. Journal of Dermatological Science, 2018, 89, 136-145.	1.9	11
28	Target-Mediated Drug Disposition Pharmacokineticâ€"Pharmacodynamic Model of Bosentan and Endothelin-1. Clinical Pharmacokinetics, 2017, 56, 1499-1511.	3.5	10
29	Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development. Scientific Reports, 2020, 10, 4410.	3.3	10
30	Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. British Journal of Clinical Pharmacology, 2012, 74, 978-989.	2.4	9
31	Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies. Clinical Pharmacokinetics, 2017, 56, 395-408.	3.5	9
32	Bayesian Regression Model with Simple Errors in Variables Structure. Journal of the Royal Statistical Society: Series D (the Statistician), 1993, 42, 571.	0.2	8
33	Modeling and Simulation to AdjustpValues in Presence of a Regression to the Mean Effect. American Statistician, 2007, 61, 302-307.	1.6	8
34	Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development. European Journal of Pharmaceutical Sciences, 2017, 109, S53-S58.	4.0	8
35	Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection. Clinical Pharmacokinetics, 2016, 55, 813-821.	3.5	7
36	Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 477-485.	2.5	7

#	Article	IF	Citations
37	Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y₁₂ receptor between selatogrel and oral P2Y₁₂ antagonists. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 735-747.	2.5	7
38	Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience. Endocrine-Related Cancer, 2005, 12, S119-S123.	3.1	6
39	Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists. Pharmaceutical Research, 2020, 37, 2.	3.5	6
40	The hierarchical Tobit model: A case study in Bayesian computing. OR Spectrum, 1994, 16, 145-154.	3.4	5
41	Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage. European Journal of Clinical Pharmacology, 2014, 70, 409-419.	1.9	5
42	Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast. Journal of Clinical Pharmacology, 2017, 57, 1042-1052.	2.0	5
43	Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2018, 49, 140-146.	2.6	5
44	Estimation of Attainment of Steadyâ€State Conditions for Compounds With a Long Halfâ€Life. Journal of Clinical Pharmacology, 2021, 61, 82-89.	2.0	5
45	PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 213-224.	1.8	5
46	Interactive Visualization and Communication for Increased Impact of Pharmacometrics. Journal of Clinical Pharmacology, 2010, 50, 140S-145S.	2.0	4
47	Visualization Concepts to Enhance Quantitative Decision Making in Drug Development. Journal of Clinical Pharmacology, 2010, 50, 130S-139S.	2.0	4
48	Tolerability and Pharmacokinetics of ACT-280778, a Novel Nondihydropyridine Dual L/T-type Calcium Channel Blocker. Journal of Cardiovascular Pharmacology, 2014, 63, 120-131.	1.9	4
49	Modelling pharmacokinetics and pharmacodynamics of the selective S1P₁ receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients. British Journal of Clinical Pharmacology, 2020, 86, 791-800.	2.4	4
50	Electronic services in statistics. Computational Statistics and Data Analysis, 1995, 19, 595-604.	1.2	3
51	Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects. European Journal of Pharmaceutical Sciences, 2016, 89, 83-93.	4.0	3
52	Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the <scp>P2Y12</scp> receptor antagonist selatogrel. Clinical and Translational Science, 2022, 15, 1906-1915.	3.1	3
53	Pediatric Development of Bosentan Facilitated by Modeling and Simulation. Paediatric Drugs, 2017, 19, 121-130.	3.1	2
54	Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects. Clinical Pharmacokinetics, 2022, 61, 687-695.	3.5	2

#	Article	IF	Citations
55	Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593â€“606, Sep/Oct 2018, DOI: 10.1002/pst.1873. Pharmaceutical Statistics, 2019, 18, 278-281.	1.3	1
56	The Case for an Unblinded Modeler in Early Clinical Development. Journal of Clinical Pharmacology, 2020, 60, 369-377.	2.0	0